Keywords: immupharma, shares, rise, cephalon, licenses, ph, ii-stage
ImmuPharma shares rise 30% as Cephalon licenses Ph II-stage SLE drug
Article | 01 December 2008
Shares in UK drug developer ImmuPharma jumped nearly 30% to 56.5 pence on November 25, after US drugmaker Cephalon licensed its mid-stage systemic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
